Mode
Text Size
Log in / Sign up
Phase 3 N=93 Randomized Triple-blind Treatment

Sphenopalatine Nerve Block for Headache Tx360

Headache · Migraine

Enrolled (actual)
93
Serious AEs
0.0%
Results posted
Jul 2015
Primary outcome: Primary: Number of Participants Who Reported a 50% or Greater Reduction in Pain at 15 Minutes as Measured on the 100mm Visual Analog Scale — 48.8; 41.3 percentage of participants

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Bupivacaine (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Indiana University
Primary completion
Dec 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Who Reported a 50% or Greater Reduction in Pain at 15 Minutes as Measured on the 100mm Visual Analog Scale
48.8; 41.3
SECONDARY
Categorical Pain Relief
13; 13; 6; 9; 3; 8
SECONDARY
Headache Free at 24 Hours
72.2; 47.5

Summary

The primary objective of this study is to evaluate the efficacy of sphenopalatine nerve block utilizing the Tx360 (device) to deliver an anesthetic agent (bupivacaine) and to assess the duration of the analgesia.

Eligibility Criteria

Inclusion Criteria

  • are 18 - 65 years of age
  • present to emergency department (ED) triage with chief complaint of crescendo-onset anterior/frontal headache (affecting frontal, temporal, orbital, maxillary, and mandible region)
  • have a normal neurological exams

Exclusion Criteria

  • are less than 18 years old or greater than 65
  • have any focal neurological dysfunction signs or symptoms
  • have a posterior/occipital/cervicogenic source predominance of headache
  • are febrile (oral temperature 37.7 C or 100 F) or signs of acute or chronic sinusitis, such as congestion, has been present more than 10 days, there is a high fever, the nasal mucus is an abnormal color, or complains of face pain or headaches
  • have self treated with pain medication or anti-emetic 4 hours prior to arrival
  • have a history of peripheral vascular disease, cancer, or HIV infection
  • are known to be pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01939314). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search